A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

An oncolytic adenovirus armed with tumor necrosis factor-α and interleukin-2 was tested in patients with advanced solid tumors. Antitumor effects were observed in both treated and non-treated lesions, leading to long-term survival in some patients. This clinical trial shows the potential of oncolytic virotherapy for patients refractory to standard therapies. See related article by Pakola et al., p. 3715.

Keyphrases

newly diagnosed
end stage renal disease
clinical trial
ejection fraction
peritoneal dialysis
rheumatoid arthritis
patient reported outcomes
risk assessment
phase ii
phase iii